Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

axitinib

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

National Institute for Health and Care Excellence NICE logo

NICE backs four treatments for juvenile idiopathic arthritis

Includes BMS' Orencia and AbbVie's Humira

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

National Institute for Health and Care Excellence NICE logo

NICE backs use of anti-cholesterol drug Ezetrol

Draft guidance reflects 'greater emphasis on managing CVD risk'

- PMLiVE

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

- PMLiVE

FDA turns down Pfizer’s Xeljanz in psoriasis

USregulator dampens the firm's hope of expanding arthritis drug's uses

National Institute for Health and Care Excellence NICE logo

NICE to speed up adoption of health technologies

Launches new Office for Market Access

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links